DT
Dioscure Therapeutics
dioscure.com
Website unreachable since Oct 30, 2026
The startup develops single-chain antibodies that specifically bind to various surface structures of the SARS-CoV spike proteins, preventing the virus from entering target cells. This technology aims to inhibit viral spread and enhance the prevention and treatment of coronavirus infections.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$3.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops single-chain antibodies that specifically bind to various surface structures of the SARS-CoV spike proteins, preventing the virus from entering target cells. This technology aims to inhibit viral spread and enhance the prevention and treatment of coronavirus infections.